As of 2015, the average cost of R-CHOP is $17,225, according to the U.S. National Library of Medicine. A cost-effective treatment for B-cell lymphoma is the drug Rituximab combined with the chemotherapy CHOP, or cyclophosphamide, doxorubicin HCl, vincristine and prednisone — otherwise known as R-CHOP.
A consensus among oncology treatments indicates the relative cost-effectiveness of R-CHOP compared with other common oncology treatments, according to Oncology magazine.
An Oncology magazine study measured the cost-effectiveness of R-CHOP by comparing the treatments of patients with B-cell lymphoma who received R-CHOP and those treated with CHOP without Rituximab. The study estimated years of life gained, costs during treatment and costs of long-term follow-up for survivors. Those who added Rituximab to their treatment resulted in a higher number of cures and lower cost per year of life gained over the trial period.